We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.
turnover in 2020
years of innovation
What we do
We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, preventing and treating disease and keeping people well with our scientific and technical know-how and talented people.
How we do it
Everyone at GSK is focused on our three long-term priorities - Innovation, Performance, Trust - underpinned by our ambition to build a more purpose and performance driven culture, aligned to our values.
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.
adjusted R&D investment in 2020
new medicines in development at FY 2020
new vaccines in development at FY 2020
We deliver growth by investing effectively in our business, developing our people and executing competitively.
turnover in 2020
adjusted operating profit in 2020
free cash flow in 2020
dividends paid in 2020
We are a responsible company. We commit to use our science and technology to address health needs, make our products affordable and available and be a modern employer.
employee engagement score on our latest employee survey
donated in 2020 to community health programmes
in Access to Medicines Index since the assessment began in 2008
Please refer to our quarterly results materials for further information on GSK’s financial performance.
US (+6% CER) sales turnover 2020
Europe (+1% CER) sales turnover 2020
International (flat CER) sales turnover 2020
Find out more about us
Discover our latest financial performance announcement and search for historical quarterly results materials
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
It began when Plough Court Pharmacy was established in 1715. Discover GSK's journey that led to the organisation we know today
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers